To explore the possible reason involved for various sensitivities of different HCC cells to MET inhibitors, we analyzed the exon14 mutation of MET (which could distinguish a unique subset of non-small cell lung carcinoma patients likely to benefit from MET inhibitors [20, 21]), copy numbers and expression levels of MET/P-MET in HCC cells [22, 23]. Here, MET is linked to non-small cell lung carcinoma.